Distinct types of lung disease caused by functional subsets of antiviral T cells.
about
Detection and quantitation of eosinophils in the murine respiratory tract by flow cytometry.CD8+ T lymphocytes in lung tissue from patients with idiopathic pulmonary fibrosisInduction of cytokines in mice with parainfluenza pneumoniaInduction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent.Alveolar epithelial cell chemokine expression triggered by antigen-specific cytolytic CD8(+) T cell recognition.Type II pneumocyte-CD8+ T-cell interactions. Relationship between target cell cytotoxicity and activation.Proliferative expansion and acquisition of effector activity by memory CD4+ T cells in the lungs following pulmonary virus infectionFas ligand is required for the development of respiratory syncytial virus vaccine-enhanced diseaseDifferential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virusVirus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection.Structural and functional consequences of alveolar cell recognition by CD8(+) T lymphocytes in experimental lung disease.Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSVVirus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infectionInfluenza virus-specific CD4+ T helper type 2 T lymphocytes do not promote recovery from experimental virus infection.A peptide mimic of a protective epitope of respiratory syncytial virus selected from a combinatorial library induces virus-neutralizing antibodies and reduces viral load in vivo.HLA class I-restricted cytotoxic T-cell epitopes of the respiratory syncytial virus fusion proteinRespiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice.Intranasal antibody prophylaxis for protection against viral disease.Microbial stimulation as an aetiologic factor in atopic disease.Interleukin 18 coexpression during respiratory syncytial virus infection results in enhanced disease mediated by natural killer cells.Chinchilla and murine models of upper respiratory tract infections with respiratory syncytial virus.Active and passive immunisation against respiratory syncytial virus.Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challengeInfluence of sex and disease severity on gene expression profiles in individuals with idiopathic pulmonary fibrosis.CD4(+) T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment.Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism.Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice.Expression of interleukin-4 by recombinant respiratory syncytial virus is associated with accelerated inflammation and a nonfunctional cytotoxic T-lymphocyte response following primary infection but not following challenge with wild-type virus.Immune responses and disease enhancement during respiratory syncytial virus infectionNovel pathways in the pathogenesis of respiratory syncytial virus disease.CD25+ natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection.Anti-IL-4 treatment at immunization modulates cytokine expression, reduces illness, and increases cytotoxic T lymphocyte activity in mice challenged with respiratory syncytial virus.Dual role of respiratory syncytial virus glycoprotein fragment as a mucosal immunogen and chemotactic adjuvantGamma interferon-dependent protection of the mouse upper respiratory tract following parenteral immunization with a respiratory syncytial virus G protein fragmentMaintenance of immunological homeostasis by Indukantha ghritha in patients with recurrent upper respiratory tract infections-a pilot study.Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells.The airway epithelium: soldier in the fight against respiratory virusesNeonatal innate immunity to infectious agents.Differential chemokine expression following respiratory virus infection reflects Th1- or Th2-biased immunopathology.
P2860
Q24657793-4D942CD0-8175-4EED-9F50-EFB1C72D2E3EQ24811707-BEEFB1CF-3DF7-4EFE-B171-EE6679CEFAD3Q28395909-3C08E80E-583F-4030-A531-BDEEFEDF2538Q30304128-595616CC-3613-4115-ACC0-3D90A131F43BQ30306117-EFF12343-82ED-4F19-8A78-A11687DE258AQ30308011-40BDA38B-3D25-4FD9-8EF0-28DCD9707611Q30436432-30F5F741-BE74-4770-8576-9CAE7DADA98BQ30436942-6B17034F-A343-4D33-BFAE-C6925AB31DC8Q30441455-0610D5EA-8359-4C9A-8419-2F71AF86CC89Q30442832-FE2297FC-718C-473E-9275-CEDC480C8B1FQ30448788-F7EA353A-032C-440F-91ED-2CC174FCEAD0Q30448968-BA57AD2A-3094-4A9D-BDA5-61C9385855ADQ30452584-7C26C2E6-02D1-4B02-A59B-985CCCA46CA8Q30465682-ADF1744A-6146-48A7-A7AA-3A470BEB3736Q32099239-F7C8AA59-09FE-492C-994B-304927E84575Q33603913-361855C5-755B-4EA0-B05F-A1344DDA29A6Q33648461-71AA2402-D658-462A-8C81-06E3EACCEFCBQ33683058-07A22A80-7214-46BE-A99E-0AA87FFA560EQ33697347-FEC38234-10AD-44EE-B3A0-DF1AF39A33B3Q33769399-42DE3F08-A773-43C9-A4AE-7633935D7EDAQ33780476-41019A29-F3DC-4388-B407-AE8BA7CD513FQ33782438-F850F12D-0E83-4307-905B-1AD11B9DFB42Q33783066-006F8B22-FCE5-45CB-BE9A-FBABA22495C5Q33785553-87D3D1FF-7A79-49A3-9E1F-319C681B3F6DQ33801890-D6E1D93F-E927-4FA1-8992-B932BAE644C2Q33820420-3F7A4C68-D839-4CC4-8FC8-B1524629894EQ33840469-9A019950-93AD-4276-9120-76F712C50DA3Q33870528-DD5F60A6-47E9-48CD-B6E2-339C8E8A649CQ33908872-356975DC-E6C5-4BBF-9723-121EF4A0FDF6Q33937152-7DB938F6-C04E-49FD-B739-DD90FA9F42E3Q33988549-BDAAD27D-C8B2-4A5A-8E9F-B989F4BD6625Q34055489-BF13B374-651A-4028-81C5-D635AD63D6E3Q34157386-8B9C2BAA-B42F-47BD-97F7-BC199517AE23Q34182385-97DD3AF3-D011-4DB9-8391-B0E35E67EA05Q34347904-1A5A93A5-37BF-4070-BF96-CF8679C9E0C2Q34414168-536C6530-3904-46E0-BB89-2943B5C8C788Q34465367-4016915E-0639-40AE-8B8C-B2248C3A6286Q34491598-DBB98DB6-CF57-4560-A4E0-5E5991295E3CQ34492674-5E4B43DF-13BC-43DD-B35A-FEAB6AF24515Q34647519-27D495EA-E880-4621-A9FE-78F3AAF3ABED
P2860
Distinct types of lung disease caused by functional subsets of antiviral T cells.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Distinct types of lung disease caused by functional subsets of antiviral T cells.
@ast
Distinct types of lung disease caused by functional subsets of antiviral T cells.
@en
type
label
Distinct types of lung disease caused by functional subsets of antiviral T cells.
@ast
Distinct types of lung disease caused by functional subsets of antiviral T cells.
@en
prefLabel
Distinct types of lung disease caused by functional subsets of antiviral T cells.
@ast
Distinct types of lung disease caused by functional subsets of antiviral T cells.
@en
P2093
P2860
P356
P1476
Distinct types of lung disease caused by functional subsets of antiviral T cells.
@en
P2093
P J Openshaw
W J Kozlowska
P2860
P356
10.1084/JEM.179.1.81
P407
P577
1994-01-01T00:00:00Z